Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine Chemoprevention in Colorectal Cancer
NCT02077777Phase 2Completed
- Sponsor
- SOFAR
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Salcrozine in colorectal cancer (CRC) (2 arms), sponsored by SOFAR. Primary endpoint: Molecular analysis of gene expression levels of mu-protocadherin and other related proteins at 3 months. Started Oct 2012; status: completed.
02
Drugs
Salcrozine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02077777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077777.